Testing dexamethasone for hospitalised patients with dengue: A pilot clinical trial

Project Status

Active

Start Date

Date published:

End Date

Date End:

Project location

Background

Dengue represents a major global health challenge, with millions of infections annually and a significant proportion occurring in Asia, alongside notable ICU admission rates and mortality. Despite this burden and the recent expansion of dengue into new regions due to changing epidemiology and climate factors, treatment remains largely supportive with limited proven therapeutic options. Corticosteroids such as dexamethasone have a strong biological rationale due to their anti-inflammatory and immunomodulatory effects, potentially reducing disease severity; however, existing evidence remains inconclusive, creating clinical uncertainty and equipoise. Therefore, there is a clear need for robust clinical trials to evaluate the effectiveness of corticosteroids in improving outcomes among hospitalized dengue patients.

Aim

  • To evaluate the feasibility and safety of conducting a parallel group randomized controlled trial of dexamethasone for patients hospitalized with dengue (phase 2b objective)
  • To evaluate the effectiveness of dexamethasone on days alive and free of organ support at day 28 for patients hospitalised with dengue (phase 3 objective- assumes success of pilot feasibility phase)

Research methodology

This is a seamless phase 2b, multicentre, open-label randomized controlled trial conducted across 10 sites in India to evaluate the effectiveness of intravenous dexamethasone in patients hospitalized with dengue. Eligible participants will be randomly allocated to one of three groups: dexamethasone 0.1 mg/kg, dexamethasone 0.2 mg/kg, or usual care. Treatment will be administered for a maximum of 5 days, or until death or hospital discharge, whichever occurs first. Participants will be followed up on Day 28 and Day 90.

Current status

The study is currently ongoing, with six sites activated and 35 patients enrolled to date. Recruitment has been limited due to the non-dengue season; however, with the approaching dengue season, an increase in patient screening and participant enrolment is anticipated.

Lead

Vivekanand Jha
Health systems science Renal and metabolic Cardiovascular health

Professor Vivekanand Jha

Executive Director, The George Institute for Global Health, India

Related People

Prof Bala Venkatesh

Program Director of Critical Care

Abhinav Bassi

Senior Research Fellow and Head of Project Operations -George Institute India

Shani S Thankachen

Associate Project Manager

Partner

The George Institute for Global Health, India

Funders

Princess Alexandra Hospital Foundation, Australia

The George Institute for Global Health, Australia

Share this Project